Epigenetics and Cancer

Organizer(s): Tony Kouzarides and Kristian Helin

Sponsored by AstraZeneca, Bayer HealthCare Pharmaceuticals, Cell Research, Cell Signaling Technology, Inc., Constellation Pharmaceuticals and Incyte Corporation. Supported by an educational grant from Celgene Corporation.

For important information on the coronavirus, please click here

Summary of Meeting:

Cancer epigenetics is a new and rapidly developing area of research. This results from the discovery that many epigenetic regulators (chromatin modifying enzymes, modification-reading proteins and chromatin-remodeling activities) are found mutated in cancers and has led to the recent approval of cancer drugs targeting epigenetic enzymes. The meeting aims to bring together scientists who are interested in understanding the connections between basic epigenetic pathways and the process of cancer. One aspect of the meeting will highlight the mechanisms by which epigenetic pathways control various biological processes. Information will be presented on chromatin and DNA modifications, chromatin complexes and ncRNAs. A second aspect will revolve around the connections between epigenetic pathways and cancer. This section will highlight genetic and epigenetic changes that take place during oncogenesis and efforts to counteract cancer with small molecule inhibitors against epigenetic regulators. The hope is to provide a forum for the interchange of information and know-how between the two converging fields of cancer research and epigenetics.

Scholarship Deadline: September 30 2014

Discounted Abstract Deadline: September 30 2014

Abstract Deadline: October 23 2014

Discounted Registration Deadline: November 24 2014

Abstacts when book is in proofing process

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

Educational grant from Celgene Corporation

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Constellation Pharmaceuticals

Epizyme, Inc.

Pfizer Inc.

We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA189412-01
Funding for this conference was made possible (in part) by 1R13CA189412-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations